Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioAffinity TechnologiesBIAF -2.64%44 Days Payable is 78.48 as of Mar. 2026, which is 10% below its 10-year median of 87.58. GuruFocus rates BIAF with a GF Score™ of 44/100 and a GF Value™ of $4.03 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, bioAffinity Technologies ranks better than 63.16% on this metric.
The historical rank and industry rank for bioAffinity Technologies's Days Payable or its related term are showing as below:
BIAF'
s Days Payable Range Over the Past 10 Years
Min: 48.56 Med: 87.58 Max: 104937.5
Current: 98.14
During the past 6 years, bioAffinity Technologies's highest Days Payable was 104937.50. The lowest was 48.56. And the median was 87.58.
BIAF's Days Payable is ranked better than 63.16% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.945
vs BIAF: 98.14
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, bioAffinity Technologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's Days Payable distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
bioAffinity Technologies's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAF) has a Days Payable of 78.48 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on bioAffinity Technologies and its competitors. This is 10% below median its historical median of 87.58. Over the past decade, bioAffinity Technologies' Days Payable has ranged from 48.56 to 104,937.50. According to the industry distribution chart, bioAffinity Technologies ranks #70 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 36.8%.
Is bioAffinity Technologies' Days Payable too high?
bioAffinity Technologies' current Days Payable of 78.48 is 10% below median its 10-year median of 87.58. Over the past 10 years, this metric has ranged from a low of 48.56 to a high of 104,937.50. The Medical Diagnostics & Research industry median Days Payable is 64.95. bioAffinity Technologies' value of 78.48 is 20.8% above this industry median. Based on the distribution chart, bioAffinity Technologies ranks #70 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' Days Payable compare to FUNI and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #70 out of 190 companies for Days Payable. This puts bioAffinity Technologies in the upper half of its industry. The industry median Days Payable is 64.95. bioAffinity Technologies' value of 78.48 is 20.8% above this benchmark. Historically, bioAffinity Technologies' own Days Payable has ranged from 48.56 to 104,937.50 over the past decade. While the company's 10-year median is 87.58 vs. the industry median of 64.95, bioAffinity Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.95, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. bioAffinity Technologies's current Days Payable of 78.48 is 20.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on bioAffinity Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current Days Payable is 78.48, which is 10% below median its own 10-year median of 87.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $4.03, compared to a current price of $0.63 — trading 84.4% below its estimated fair value. The current Days Payable is 78.48, which is 10% below median its 10-year median of 87.58 and 20.8% above the Medical Diagnostics & Research industry median of 64.95. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current Days Payable is 78.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.63 is trading 84.4% below its estimated GF Value™ of $4.03.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
Days Payable: 78.48 (10% below median its 10-year median of 87.58)
GF Value™: $4.03 vs. price of $0.63 (84.4% below fair value)
Industry Position: 20.8% above the Medical Diagnostics & Research median (#70 of 190)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
